News
ATHA
--
0.00%
--
Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Ka...
GlobeNewswire · 5d ago
3 Net-Net Working Capital Stocks
GuruFocus News · 02/16 14:21
Athira Pharma Announces Exercise of Underwriters' Option to Purchase Additional Shares
Athira Pharma, Inc., (Nasdaq: ATHA) ("Athira"), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that the underwriters of its public offering have e...
GlobeNewswire · 02/10 21:35
CLSN, RIOT, POLA and MARA among midday movers
Gainers: Vinco Ventures (BBIG) +312%.ADiTx Therapeutics (ADTX) +90%.Qutoutiao (QTT) +65%.Ideal Power (IPWR) +51%.BiondVax Pharmaceuticals (BVXV) +39%.Celsion (CLSN) +34%.Polar Power (POLA) +33%.Addex Therapeutics (ADXN) +28%.Pioneer Power Solutions (PPSI) ...
Seekingalpha · 01/21 17:41
DJ Athira Pharma Shares Drop 13% After Public Offering Prices
Dow Jones · 01/21 14:55
MARA, RIOT, FCEL among premarket losers
Cancer Genetics (CGIX) -18%.Obalon Therapeutics (OBLN) -17%.Adamis Pharmaceuticals (ADMP) -17%.Marathon Patent Group MARA -11% as Bitcoin crumbles despite good news rolls in.Riot Blockchain RIOT -11% as Bitcoin crumbles despite good news rolls in.Foresight...
Seekingalpha · 01/21 13:24
Athira Pharma Priced 4M Share Public Offering of Common Stock @$22.50/Share
Athira Pharma, Inc., (NASDAQ: ATHA) announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $22.50 per share. All of the shares of common stock are being offered by Athira.
Benzinga · 01/21 10:45
Athira Pharma prices equity offering at $22.50
Athira Pharma (ATHA) has priced its public offering of 4M common shares at $22.50/share, for expected gross proceeds of $90M.Underwriters' over-allotment is an additional 600K shares.Closing date is January 25.Shares down
Seekingalpha · 01/21 10:32
Athira Pharma Prices $90 Million Public Offering
MT Newswires · 01/21 03:38
*DJ Goldman Sachs, Jefferies, Stifel Acting as Bookrunning Managers for Athira Pharma Offering >ATHA
Dow Jones · 01/21 00:45
*DJ Athira Pharma Grants Underwriters 30-Day Option to Buy Up to 600,000 Additional Shares >ATHA
Dow Jones · 01/21 00:44
*DJ Athira Pharma Expects $90.0M in Gross Proceeds From Offering >ATHA
Dow Jones · 01/21 00:41
*DJ Athira Pharma Prices Public Offering of 4.0M Shares at $22.50 Each >ATHA
Dow Jones · 01/21 00:40
BRIEF-Athira Pharma Announces Pricing Of Public Offering Of Common Stock
reuters.com · 01/21 00:37
Athira Pharma Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash., Jan 20, 2021 (GLOBE NEWSWIRE via COMTEX) -- BOTHELL, Wash., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) ("Athira"),...
GlobeNewswire · 01/21 00:36
Athira Pharma Announces Pricing of Public Offering of Common Stock
Athira Pharma, Inc., (Nasdaq: ATHA) ("Athira"), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its underwritten public offering of ...
GlobeNewswire · 01/21 00:35
Athira Pharma Announces Pricing of Public Offering of Common Stock
GlobeNewswire · 01/21 00:35
Athira Pharma Announces Pricing of Public Offering of Common Stock
GlobeNewswire · 01/21 00:35
Athira Pharma to sell 4M shares of common stock
Athira Pharma ([[ATHA]] -3.7%) trades lower as it announced an underwritten public offering of 4M shares of its common stock.All of the shares in the proposed offering will be sold by
Seekingalpha · 01/19 17:42
DJ Athira Pharma Shares Slip on Planned Stock Offering >ATHA
Dow Jones · 01/19 16:37
Webull provides a variety of real-time ATHA stock news. You can receive the latest news about Athira Pharma, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ATHA
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.